Illumina Inc (ILMN) 139.64 $ILMN
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 115.74 (+0.74), NXTM: 22.87 (-0.04), GWPH: 96.35 (+1.52), ILMN: 139.64 (-1.61)
Illumina Applauds FDA's Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing
BusinessWire - Thu Jul 07, 8:20AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it supports the Food and Drug Administration (FDA) in their efforts to provide a flexible and streamlined approach to the oversight of next generation sequencing (NGS) diagnostic tests, as represented by FDA's release of two new draft guidance documents. The FDA draft guidances are part of the larger Precision Medicine Initiative announced by President Obama in his 2015 State of the Union address.
ILMN: 139.64 (-1.61)
Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina, Inc.
BusinessWire - Thu Jul 07, 8:15AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a settlement with Illumina, Inc. (Nasdaq: ILMN) that included a payment of $21 million to Enzo in an action brought in Delaware Federal District Court by Enzo alleging infringement of its U.S. Patent No. 7,064,197, entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids.
ENZ: 6.18 (+0.24), ILMN: 139.64 (-1.61)
Downgrade Alert for Illumina (ILMN)
Comtex SmarTrend(R) - Wed Jul 06, 3:26AM CDT
Illumina (NASDAQ:ILMN) was downgraded from Equal Weight to Underweight at Morgan Stanley today. The stock closed yesterday at $138.67 on volume of 2.1 million shares, above average daily volume of 1.8 million. Over the past year, Illumina has traded in a range of $25.57 to $242.37 and closed yesterday at $138.67, 442% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 1.2% while the 50-day MA has declined 0.8%.
ILMN: 139.64 (-1.61)
Illumina Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 05, 1:30PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $132.65 to a high of $137.48. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $135.31 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 139.64 (-1.61)
Illumina, MolecularMD to Co-Develop Oncology Diagnostics
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 8:07AM CDT
The collaboration will combine Illumina's (ILMN) expertise in NGS technology with MolecularMD's experience in developing molecular testing for new oncology drugs
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), LMAT: 13.64 (-0.06), ILMN: 139.64 (-1.61)
Illumina, Inc. (ILMN) - Product Pipeline Market Analysis Report, 2016: Radiant Insights
GlobeNewswire - Thu Jun 23, 5:39AM CDT
Illumina, Inc. (Illumina) provides sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations.
ILMN: 139.64 (-1.61)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 46.49 (-0.16), LMAT: 13.64 (-0.06), ILMN: 139.64 (-1.61), GHDX: 27.91 (-0.21)
Illumina Announces Initial Customer Orders for the Global Screening Array
BusinessWire - Thu Jun 16, 8:00AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12 customers for its new Infinium(R) Global Screening Array (GSA). In total, the company has received orders for more than 3 million samples of the new consortia-developed array. Initial customers include human disease researchers at The Broad Institute and deCODE Genetics, health systems Avera Health, Codigo46, Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford Health and UCLA Health System, genomic service providers Centre National de Genotypage, Human Genomics Facility HuGeF, Erasmus MC, Life and Brain, and consumer genomics company 23andMe, Inc.
ILMN: 139.64 (-1.61)
Watch for Illumina to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 2:51PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $139.41 to a high of $143.77. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.10 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 139.64 (-1.61)
Xcell Biosciences to Present Data From its Avatar System at ISSCR Annual Meeting
BusinessWire - Mon Jun 13, 6:30AM CDT
Xcell Biosciences, Inc., announced today that it will co-present a poster at the upcoming International Society for Stem Cell Research (ISSCR) annual meeting alongside Illumina, Inc. (NASDAQ: ILMN), an early investor in the company. The poster, "Creating a tunable stem cell: modulation of oxygen and atmospheric pressure during culture alters signaling pathways governing stem cell maintenance and differentiation," features data on the impact of various environmental conditions on stem cell state. The meeting takes place June 22-25 in San Francisco.
ILMN: 139.64 (-1.61)
Look for Shares of Illumina to Potentially Rebound after Yesterday's 1.52% Sell Off
Comtex SmarTrend(R) - Thu Jun 09, 2:21PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $142.73 to a high of $146.11. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $143.52 on volume of 391,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 139.64 (-1.61)
How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
PR Newswire - Thu Jun 09, 7:00AM CDT
Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning ActiveWallSt.com features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:
ZFGN: 6.92 (+0.31), CLVS: 14.70 (-0.03), NLNK: 11.62 (-0.17), ILMN: 139.64 (-1.61)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 252.54 (+1.24), VRTX: 90.10 (+1.14), PXD: 153.00 (-0.72), ALXN: 125.30 (+0.88), HAL: 44.48 (-0.55), EOG: 82.90 (+0.36), AMGN: 160.18 (-0.92), ILMN: 139.64 (-1.61), XOM: 93.89 (+0.35), COP: 42.45 (+0.15), JUNO: 27.33 (-0.48), CVX: 105.39 (+0.62), OXY: 76.20 (+0.07), REGN: 375.74 (-2.61)
InvestorsObserver releases covered-call reports for SolarCity, Illumina, Nabors Industries, Amazon.com and Salesforce.com
PR Newswire - Tue Jun 07, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SCTY, ILMN, NBR, AMZN and CRM.
AMZN: 753.78 (+7.97), SCTY: 24.52 (+0.72), NBR: 9.38 (-0.44), ILMN: 139.64 (-1.61), CRM: 81.66 (+0.77)
Alexandria Real Estate Equities, Inc. Announces Key Second Quarter 2016 Deliveries from Highly Leased Value-Creation Pipeline and Significant Projected Fourth Quarter 2016 Deliveries
PR Newswire - Tue Jun 07, 7:30AM CDT
Alexandria Real Estate Equities, Inc. (NYSE: ARE), a real estate investment trust uniquely focused on world-class collaborative science and technology campuses in urban innovation clusters, today announced the early delivery of a ground-up development of 295,609 rentable square feet (RSF) at 5200 Illumina Way, Building 6, to Illumina, Inc. in San Diego's University Town Center (UTC) submarket.
ARE: 103.73 (+0.94), ILMN: 139.64 (-1.61)
Illumina Announces Donald Danforth Plant Science Center to Receive Agricultural Greater Good Initiative Grant to Improve Food Security in Sub-Saharan Africa
BusinessWire - Tue Jun 07, 5:00AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that the Donald Danforth Plant Science Center is the 2016 recipient of the Agricultural Greater Good Initiative grant. Their project aims to optimize breeding strategies for improving the yield and stress tolerance of grain sorghum (Sorghum bicolor), a critical source of nutrition to millions of people living in Sub-Saharan Africa. The Illumina Agricultural Greater Good Initiative grant program is designed to help identify measures that can increase crop yields and improve livestock welfare and productivity to alleviate poverty and hunger in the developing world.
ILMN: 139.64 (-1.61)
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 115.74 (+0.74), NXTM: 22.87 (-0.04), GWPH: 96.35 (+1.52), ILMN: 139.64 (-1.61)
Illumina Applauds FDA's Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing
BusinessWire - Thu Jul 07, 8:20AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it supports the Food and Drug Administration (FDA) in their efforts to provide a flexible and streamlined approach to the oversight of next generation sequencing (NGS) diagnostic tests, as represented by FDA's release of two new draft guidance documents. The FDA draft guidances are part of the larger Precision Medicine Initiative announced by President Obama in his 2015 State of the Union address.
ILMN: 139.64 (-1.61)
Enzo Biochem's Life Sciences Unit Reaches $21 Million Patent Infringement Settlement in Delaware With Illumina, Inc.
BusinessWire - Thu Jul 07, 8:15AM CDT
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its subsidiary, Enzo Life Sciences, Inc., has reached and finalized a settlement with Illumina, Inc. (Nasdaq: ILMN) that included a payment of $21 million to Enzo in an action brought in Delaware Federal District Court by Enzo alleging infringement of its U.S. Patent No. 7,064,197, entitled System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids.
ENZ: 6.18 (+0.24), ILMN: 139.64 (-1.61)
Downgrade Alert for Illumina (ILMN)
Comtex SmarTrend(R) - Wed Jul 06, 3:26AM CDT
Illumina (NASDAQ:ILMN) was downgraded from Equal Weight to Underweight at Morgan Stanley today. The stock closed yesterday at $138.67 on volume of 2.1 million shares, above average daily volume of 1.8 million. Over the past year, Illumina has traded in a range of $25.57 to $242.37 and closed yesterday at $138.67, 442% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 1.2% while the 50-day MA has declined 0.8%.
ILMN: 139.64 (-1.61)
Illumina Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 05, 1:30PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $132.65 to a high of $137.48. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $135.31 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 139.64 (-1.61)
Illumina, MolecularMD to Co-Develop Oncology Diagnostics
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 8:07AM CDT
The collaboration will combine Illumina's (ILMN) expertise in NGS technology with MolecularMD's experience in developing molecular testing for new oncology drugs
BSX: 23.77 (-0.13), ICUI: 115.74 (+0.74), LMAT: 13.64 (-0.06), ILMN: 139.64 (-1.61)
Illumina, Inc. (ILMN) - Product Pipeline Market Analysis Report, 2016: Radiant Insights
GlobeNewswire - Thu Jun 23, 5:39AM CDT
Illumina, Inc. (Illumina) provides sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company's portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations.
ILMN: 139.64 (-1.61)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 46.49 (-0.16), LMAT: 13.64 (-0.06), ILMN: 139.64 (-1.61), GHDX: 27.91 (-0.21)
Illumina Announces Initial Customer Orders for the Global Screening Array
BusinessWire - Thu Jun 16, 8:00AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12 customers for its new Infinium(R) Global Screening Array (GSA). In total, the company has received orders for more than 3 million samples of the new consortia-developed array. Initial customers include human disease researchers at The Broad Institute and deCODE Genetics, health systems Avera Health, Codigo46, Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford Health and UCLA Health System, genomic service providers Centre National de Genotypage, Human Genomics Facility HuGeF, Erasmus MC, Life and Brain, and consumer genomics company 23andMe, Inc.
ILMN: 139.64 (-1.61)
Watch for Illumina to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Mon Jun 13, 2:51PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $139.41 to a high of $143.77. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.10 on volume of 388,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 139.64 (-1.61)
Xcell Biosciences to Present Data From its Avatar System at ISSCR Annual Meeting
BusinessWire - Mon Jun 13, 6:30AM CDT
Xcell Biosciences, Inc., announced today that it will co-present a poster at the upcoming International Society for Stem Cell Research (ISSCR) annual meeting alongside Illumina, Inc. (NASDAQ: ILMN), an early investor in the company. The poster, "Creating a tunable stem cell: modulation of oxygen and atmospheric pressure during culture alters signaling pathways governing stem cell maintenance and differentiation," features data on the impact of various environmental conditions on stem cell state. The meeting takes place June 22-25 in San Francisco.
ILMN: 139.64 (-1.61)
Look for Shares of Illumina to Potentially Rebound after Yesterday's 1.52% Sell Off
Comtex SmarTrend(R) - Thu Jun 09, 2:21PM CDT
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $142.73 to a high of $146.11. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $143.52 on volume of 391,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 139.64 (-1.61)
How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
PR Newswire - Thu Jun 09, 7:00AM CDT
Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning ActiveWallSt.com features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:
ZFGN: 6.92 (+0.31), CLVS: 14.70 (-0.03), NLNK: 11.62 (-0.17), ILMN: 139.64 (-1.61)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 252.54 (+1.24), VRTX: 90.10 (+1.14), PXD: 153.00 (-0.72), ALXN: 125.30 (+0.88), HAL: 44.48 (-0.55), EOG: 82.90 (+0.36), AMGN: 160.18 (-0.92), ILMN: 139.64 (-1.61), XOM: 93.89 (+0.35), COP: 42.45 (+0.15), JUNO: 27.33 (-0.48), CVX: 105.39 (+0.62), OXY: 76.20 (+0.07), REGN: 375.74 (-2.61)
InvestorsObserver releases covered-call reports for SolarCity, Illumina, Nabors Industries, Amazon.com and Salesforce.com
PR Newswire - Tue Jun 07, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SCTY, ILMN, NBR, AMZN and CRM.
AMZN: 753.78 (+7.97), SCTY: 24.52 (+0.72), NBR: 9.38 (-0.44), ILMN: 139.64 (-1.61), CRM: 81.66 (+0.77)
Alexandria Real Estate Equities, Inc. Announces Key Second Quarter 2016 Deliveries from Highly Leased Value-Creation Pipeline and Significant Projected Fourth Quarter 2016 Deliveries
PR Newswire - Tue Jun 07, 7:30AM CDT
Alexandria Real Estate Equities, Inc. (NYSE: ARE), a real estate investment trust uniquely focused on world-class collaborative science and technology campuses in urban innovation clusters, today announced the early delivery of a ground-up development of 295,609 rentable square feet (RSF) at 5200 Illumina Way, Building 6, to Illumina, Inc. in San Diego's University Town Center (UTC) submarket.
ARE: 103.73 (+0.94), ILMN: 139.64 (-1.61)
Illumina Announces Donald Danforth Plant Science Center to Receive Agricultural Greater Good Initiative Grant to Improve Food Security in Sub-Saharan Africa
BusinessWire - Tue Jun 07, 5:00AM CDT
Illumina, Inc. (NASDAQ: ILMN) today announced that the Donald Danforth Plant Science Center is the 2016 recipient of the Agricultural Greater Good Initiative grant. Their project aims to optimize breeding strategies for improving the yield and stress tolerance of grain sorghum (Sorghum bicolor), a critical source of nutrition to millions of people living in Sub-Saharan Africa. The Illumina Agricultural Greater Good Initiative grant program is designed to help identify measures that can increase crop yields and improve livestock welfare and productivity to alleviate poverty and hunger in the developing world.
ILMN: 139.64 (-1.61)
